What the FDA labels say about taking them together
Certolizumab and methotrexate
Certolizumab's FDA label of February 24, 2026 names methotrexate in its boxed warning section; the methotrexate labels PlainMeds reads (4) do not name certolizumab. The certolizumab label: “Patients greater than 65 years of age, patients with co-morbid conditions, and/or patients taking concomitant immunosuppressants may be at a greater risk of infection.”
Check it at the source: the certolizumab FDA label on DailyMed (effective February 24, 2026, UCB, Inc.); the methotrexate FDA label on DailyMed (effective May 27, 2026, Accord Healthcare Inc.).
What does the certolizumab label say about methotrexate?
Certolizumab label, boxed warningMost patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids.
Certolizumab label, warnings and precautionsPatients greater than 65 years of age, patients with co-morbid conditions, and/or patients taking concomitant immunosuppressants (e.g. corticosteroids or methotrexate) may be at a greater risk of infection.
Source: FDA drug label (Cimzia), BLA125160 (Ucb Inc), as published by UCB, Inc., effective February 24, 2026 (SPL set b4c2c9dc-a0bb-4d64-a667-a67ebe88392d), via openFDA; the full label on DailyMed
What does the methotrexate label say about certolizumab?
Methotrexate's label (effective May 27, 2026) and its 3 other brand-application labels do not name certolizumab in these sections. A label lists what its studies and reports found; it is not a complete list.
Source: FDA drug label (Methotrexate), Accord Healthcare Inc., effective May 27, 2026 (SPL set 874c7f43-a3be-4236-89cc-24c44e3c5813), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Certolizumab | Methotrexate | |
|---|---|---|
| Labeled for | Rheumatoid arthritis, Crohn's disease and ulcerative colitis, Psoriasis | Rheumatoid arthritis, Psoriasis, Leukemia, lymphoma and myeloma, Breast cancer |
| Boxed warning | Yes | Yes |
| Pharmacy cost (NADAC) | $6,094.02 per syringe 2x200 mg/mL syringe kit | $0.158 per tablet 2.5 mg tablet |
| Shortage now | No current entry | In shortage |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once